Nitazoxanide (NTZ) is a broad-spectrum antiparasitic drug with low bioavailability due to its poor aqueous solubility, classified as a Biopharmaceutical Classification System (BCS) class II drug. This study aimed to improve the understanding of NTZ nanocrystalline suspensions produced via the solvent-antisolvent technique. NTZ was extracted from commercially available coated tablets and characterized using DSC, TG, UV-Vis, and FTIR, revealing the presence of impurities likely from excipients. Nanocrystalline suspensions were prepared using three different stabilizers (Lecithin, Poloxamer 188, and Tween® 80) and evaluated for particle size distribution (PSD) and polydispersity index (PDI) over a one-week stability study. Poloxamer 188 was the most effective in reducing particle size (934.7 nm), though Lecithin achieved a more favorable PDI (0.289), indicating better particle uniformity. These findings suggest the solvent-antisolvent technique is a promising approach for producing NTZ nanocrystalline suspensions, but further reduction in particle size and exploration of alternative stabilizers are needed to optimize stability and performance.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: